secwatch / observer
8-K filed August 11, 2022, 7:59 PM ET ticker AVTX CIK 0001534120
leadership confidence high sentiment neutral materiality 0.30

Two Armistice Capital directors resign from Avalo board; CEO Garry Neil appointed Chairman

Avalo Therapeutics, Inc.

item 1.01item 5.02item 8.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Garry Neil

Chairman of the Board
AVTX · Avalo Therapeutics, Inc.
Filed
August 11, 2022, 7:59 PM ET
The Board appointed the Company’s President and Chief Executive Officer and Board member, Dr. Garry Neil, M.D., to replace Mr. Boyd as Chairman of the Board.
Departed

Keith Maher

Director
AVTX · Avalo Therapeutics, Inc.
Effective
2022-08-08
Filed
August 11, 2022, 7:59 PM ET
On August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) that they have resigned from their positions on the Board.
Departed

Steven Boyd

Director
AVTX · Avalo Therapeutics, Inc.
Effective
2022-08-08
Filed
August 11, 2022, 7:59 PM ET
On August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) that they have resigned from their positions on the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Garry Neil was appointed as Chairman of the Board at Avalo Therapeutics, Inc..

Action
appointed
Role
Chairman of the Board
Exact text from the filing
The Board appointed the Company’s President and Chief Executive Officer and Board member, Dr. Garry Neil, M.D., to replace Mr. Boyd as Chairman of the Board.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Keith Maher resigned as Director at Avalo Therapeutics, Inc..

Action
resigned
Role
Director
Exact text from the filing
On August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) that they have resigned from their positions on the Board.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Steven Boyd resigned as Director at Avalo Therapeutics, Inc..

Action
resigned
Role
Director
Exact text from the filing
On August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) that they have resigned from their positions on the Board.
View on SEC.gov

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001628280-22-022439
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.